Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 5Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neuroblastoma 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Graft vs Host Disease 1Central Nervous System Neoplasms 1

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Hematologic Diseases × Rituximab × Clear all
NCT02484053 2018-07-11

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

Baylor College of Medicine

Phase EARLY_PHASE1 Completed
20 enrolled
Lymphoid

Graft vs Host Disease, Hematologic Diseases, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡